Summary
Resistance to chemotherapy in brain tumors is complex and may involve multiple mechanisms. For commonly used drugs, such as nitrosoureas and platinum compounds, major mechanisms may involve increaded DNA repair or removal of the drug-DNA adducts. For water soluble nitrosoureas and also for platinum compounds, other mechanisms, such as alteration in drug transport, may be important. Another major mechanism may involve glutathione and glutathione-S-transferase pathways. For vinca alkaloids and epipodophyllotoxins p-glycoprotein mediated MDR appears to be the major feature in drug resistance. In addition, alteration of tubulin and topoisomerase II have been described in resistance to vinca alkaloids and epipodophyllotoxins respectively. Recently, increased multidrug resistance associated protein gene expression has been found in glioma cells and brain tumor samples; its clinical significance requires further investigation.
Similar content being viewed by others
References
Feun LG, Lee YY, Charnsangavej C, Yung WKA, Savaraj N, Carrasco CH, Gianturco C, Wallace S: New drugs and delivery techniques inProgress in Experimental Tumor Research Vol 29 p 131–139 (Karger, Basel 1985)
Grossman SA, Wharam M, Sheidler V, Zeltzman M, Zinreich J, Moynihan T, Gilbert M, Ahn H: BCNU/Cisplatin (BIC) followed by radiation in poor prognosis patients with high grade astrocytomas. Proc Am Soc Clin Oncol 11: 149, 1992
Rosenblum ML, Gerosa MA, Bodell WJ, Talcott RL: Tumor cell resistance inProgress in Experimental Research Vol 27, p 191–211 (Karger, Basel 1984)
Phillips PC: Antineoplastic resistance in brain tumors inNeurologic Clinics 9: 383–404, 1991 (May)
Eagan RT, Scott: Evaluation of prognostic factors in chemotherapy of recurrent brain tumors. J Clin Oncol 12: 38–44, 1983
Wheeler G: A review of studies of the mechanism of action of nitrosourea. Cancer Chemother 30: 87–119, 1976
Schein PS, Heal J, Green D, Woolley PV: Pharmacology of nitrosourea antitumor agents. Antibiot Chemother 23: 64–75, 1976
Heal TM, Fox PA, Schein PS: Effect of carbamoylation on the repair of nitrosourea-induced DNA-alkylation damage in L1210 cells. Cancer Res 39: 82–89, 1979
Erickson LC, Bradley MO, Ducore JM, Ewig RA, Kohn KW: DNA crosslinking and cytotoxicity in normal and transformed human cells treated with antitumor nitrosoureas. Proc Natl Acad Sci USA 77: 467–471, 1980
Erickson LC, Laurent G, Sharkey NA, Kohn KW: DNA crosslinking and monadduct repair in nitrosourea-treated human tumor cells. Nature (Lond.) 228: 727–729, 1980
Bodell WJ, Rupniak NTR, Rasmussen J, Morgan WF, Rosenblum ML: Reduced level of DNA crosslinks and sister chromatid exchanges in 1,3-bis(2-chloroethyl)-l-nitrosourea resistant rat brain tumor cells. Cancer Res 44: 3763–3767, 1984
Bodell WJ, Aida T, Berger MS, Rosenblum ML: Increased repair of 0 6-alkylguanine DNA adduets in glioma derived human cells resistant to the cytotoxic and cytogenetic effects of 1,3-bis(2-chloroethyl)-l-nitrosourea. Carcinogenesis 7: 879–883, 1986
Brent TP: Suppression of cross-link formation in chloroethylnitrosourea-treated DNA by an activity in extracts of human leukemic lymphoblasts. Cancer Res 44: 1887–1892, 1984
Robinson P, Harris AL, Goldsmith I, Lindahl T: Cross-linking of DNA induced by chloroethylnitrosourea is prevent by O6-methylguanine-DNA methyltransferase. Nucleic Acids Res 11: 7743–7758, 1983
Day RS, Ziolkowski CH, Scudiero DA, Meyer SA, Lubiniecki A, Girardi AJ, Galloway SM, Bynum GD. Defective repair of alkylated DNA by human tumor and SV 40-transformed human cell strains. Nature (Lond) 288: 724–727, 1980
Day RS, Ziolkowski CH, Scudiero DA, Meyer SA, Mattern MR: Human tumor cell strains defective in the repair of alkylation damage. Carcinogenesis (Lond) 1: 21–32, 1980
Scudiero DA, Meyer SA, Clatterbuck BE, Mattern MR, Ziolkowski CH, Day RS: Sensitivity of human cell strains having different abilities to repair 06-methylguanine in DNA to inactivation by alkylating agents including chloroethylnitrosoureas. Cancer Res 44: 2467–2474, 1984
Yarosh DB: The role of 06-methylguanine-DNA methyltransferase in cell survival, mutagenesis and carcinogenesis. Mutat Res 145: 1–16, 1985
Sariban G, Kohn KW, Zlotogorski C, Laurent G, D'lncalci M, Day R, Smith BN, Kornbluth P, Erickson LC: DNA cross-linking response of human malignant glioma cell strains to chloroethylnitrosoureas, cisplatin and diaziquone. Cancer Res 47: 3988–3994, 1987
Noe AJ, Malapetsa A, McQuillan AC, Panasci LC: Bischloroethylnitrosourea (BCNU) Resistance in clinical glioma samples and human glioma cell lines may correlate with expression of 0 6-methylguanine-DNA methyltransferase (MGMT) and metallothionein (hMT) mRNA. Proc Am Soc Clin Oncol 11: 150, 1992
Bodell WJ, Tokuda K, Ludlum DB: Differences in DNA alkylation products formed in sensitive and resistant human glioma cells treated with N-(2-chloroethyl)-N-nitrosourea. Cancer Res 48: 4489–4492, 1988
Hill DL, Kirk MC, Struck RF: Microsomal metabolism of nitrosoureas. Cancer Res 35: 296–301, 1975
Hill DL, N,N’-Bis(2-chloroethyl)-N-nitrosourea, a substrate for glutathione (GSH) S-transferase. Proc Am Assoc Cancer Res 17: 52, 1976
Talcott RE, Levin VA: Glutathione-dependent denitrosation of BCNU: Nitrite release catalyzed by mouse liver cytosolin vitro. Drug Metab Dispos 11: 175–176, 1983
Smith MT, Evans CG, Doane-Setzar P, Castro VM, Tahir MK, Mannervik B: Denitrosation of 1,3-bis(2-chloroethyl) 1-nitrosourea by class mu glutathione transferases and its role in cellular resistance in rat brain tumor cells. Cancer Res 49: 2621–2625, 1989
Yoshina T, Shimizu K, Ushio Y, Haykawa T, Mogami H, Sakomota: The mechanisms and overcoming of resistance in ACNU-resistant sublines of C6 and 9L rat glioma. J Neuro-Onc 5: 195–207, 1987
Shapiro JR, Ebrahim SAD, Mohamed AN, Pu P-Y, Shapiro WR: BCNU-sensitivity in parental cells and clones from four freshly resected near-diploid human gliomas: an astrocytoma, an anaplastic astrocytoma and two glioblastoma multiforme. J Neuro-Oncol 15: 209–227, 1993
Freedman HS, Dolan ME, Moschel RC, Pegg AE, Felker GM, Rich J, Bigner DD, Schold Jr SC: Enhancement of nitrosourea activity in medulloblastoma and glioblastoma multiforme. J Natl Cancer Inst 84: 1926–1931, 1992
Zlotogorski C, Erickson LC: Pretreatment of normal human fibroblasts and human colon carcinoma cells with MNNG allows chloroethylnitrosourea to produce DNA interstrand crosslinks not observed in cells treated with chloroethylnitrosourea alone. Carcinogenesis (Lond) 4: 759–763, 1983
Zlotogorski C, Erickson LC: Pretreatment of human colon tumor cells with DNA methylating agents inhibits their ability to repair chloroethyl monoadducts. Carcinogenesis (Lond) 5: 83–87, 1984
Yarosh DB, Hurst-Calderone S, Babich MA, Day RS: Inactivation of 06-methylguanine-DNA-methyltransferase and sensitization of human tumor cells to killing by chloroethylnitrosourea by 06-methylguanine as a free base. Cancer Res 46: 1663–1668, 1986
Dolan ME, Corsico CD, Pegg AE: Exposure of Hela cells to 06-alkylguanines increases sensitivity to the cytotoxic effects of alkylating agents. Biochem Biophys Res Commun 132: 178–185, 1985
Aida T, Cheitlin RC, Bodell WJ: Inhibition of 06-alkylguanine-DNA-alkyltransferase potentiates cytotoxicity and induction of SCEs in human glioma cells resistant to 1,3-bis (2-chloroethyl)-1-nitrosourea. Carcinogenesis (Lond) 8: 1219–1223, 1987
Silber JR, Bobola MS, Evers TG, Muramoto M, Berger MS: 06-alkylguanine DNA-alkyltransferase is not a major determinant of sensitivity to 1,3 bis (2-chloroethyl)-l-nitro-sourea in four medulloblastoma cell lines. Oncology Res 4: 241–248, 1992
Crone TM, Pegg AE: A single amino acid change in human 06-alkylguanine-DNA-alkyltransferase decreasing sensitivity to inactivation by 06-benzylguanine. Can Res 53: 4750–4753, 1993
Hung DT, Deen DF, Marton LJ: Differential response to 1,3-bis(2-chloroethyl)-1-nitrosourea in drug resistant and sensitive 9L rat brain tumor cells pretreated with α difluoromethylornithine and 6-thioguanine. In J Cancer 44: 658–660, 1989
Prado M, Rodriguez L, Chamberlain M, Silver P, Levin VA: Treatment of resistant gliomas with 1,3 bis (2-chlo-roethyl)-1-nitrosourea and α difluoromethylornithine. Neurosurgery 24: 806–809, 1989
Wong KH, Waller A, Wheeler KT: 2-Nitroimidazole potentiation of nitrosourea induced cytotoxicity in subcutaneous implants of rat 9L brain tumor cells. J Neuro-Onc 11: 17–25, 1991
DaSilva VF, Feeley M, Raaphorst: Hyperthermia potentiation of BCNU toxicity in BCNU-resistant human glioma cells. J Neuro Onc 11: 37–31, 1991
Hunter KJ, Deen DF, Marton LJ: Differential response to 1,3-bis(2-chloroethyl)-l-nitrosourea in drug resistant and sensitive 9L rat brain tumor cells pretreated with α difluoromethylornithine and 6-thioguanine. Int J Cancer 44: 658–600, 1989
Levin VA, Prados MD: Treatment of recurrent gliomas and raetastatic brain tumors with a polydrug protocol designed to combat nitrosourea resistance. J Clin Oncol 10: 766–771
Aid T, Bodell WJ: Cellular resistance to chloroethylnitrosoureas, nitrogen mustard, oral cis-diamminedichloroplatinum (II) in human glial-derived cell lines. Cancer Res 47: 1361–1366, 1987
Feun LC, Wallace S, Stewart PJ, Chuang VP, Yung WKA, Leavens ME, Burgess MA, Savaraj N, Benjamin RS, Young JE, Tang RA, Hardel S, Mavligit G, Fields WS: Intracarotid infusion of cis-diamminedichloroplatinum in the treatment of recurrent malignant brain tumors. Cancer 54: 794–799, 1984
Khan AB, D'Souza BJ, Wharam MD, Champion LAA, Sinks LF, Woo SY, McCullough DC, Leventhal BG: Cisplatin therapy in recurrent childhood brain tumors. Cancer Treat Rep 66: 2013–2020, 1982
Reed T: Platinum analogs inCancer — Principles and Practice of Oncology, pp 390–400 (Lippincott, Phil 1993)
Andrews PA, Mann SC, Velury Set al.: Cisplatin uptake mediated cisplatin resistance in human ovarian carcinoma cells, in Proc 5th International Symposium on Platinum and other metal coordination compounds in Cancer Chemotherapy, Padua, Italy, 1988. Boston, MA, Martinus Nijhoff, 1988, pp 248–254
Kraker AJ, Moore CW: Accumulation of cis-diamminedichloroplatinum (I) and platinum analog by platinum-resistant murine leukemia cellsin vitro. Cancer Res 48: 9–13, 1988
Andrews PA, Velury S, Mann SCet al.: Cis-diamminedichloroplatinum (II) accumulation in sensitive and resistant human ovarian carcinoma cell. Cancer Res 48: 68–73, 1989
Scanlon KJ, Kashani-Sabet M, Miyachi Het al.: Molecular basis of cisplatin resistance in human carcinomas, model systems. Anticancer Res 9: 1301–1312, 1989. cells. J Neuro-Onc 3: 343–348, 1986
De Graeff A, Slebos RJC, Rodenhuis S: Resistance to cis-platin and analogues; mechanism and potential clinical implications. Cancer Chemother Pharmacol 22: 325, 330
Mincura K, Ishiyama Y, Kowada M: Cross-resistance pattern in brain tumor cells resistant to antitumor chloroethyl-nitrosoureas. Neuro Res 14: 45–48, 1992
Oberc-Greenwood MA, Smith BN, Cooke C, Pepin C, Kornblith PL: Selective cytoplasmic and membrane changes induced by cisplatinum. J Neuro-Oncol 9: 191–199, 1990
Goodwin JW, Bottomley RH, Vaugh CB, Frank J, Pugh RP: Phase II evaluation of anguidine in central nervous system tumors: A Southwest Oncology Group study. Cancer Treat Rep 67: 285–286, 1983
Hromas R, Meyor R, Jenkins S, Barlugre B: Anguidine enhances cisplatinum-induced DNA cross-links in Chinese hamster ovary cells. Proc Assoc Cancer Res 25: 370, 1904
Hromas RA, Yung WKA: Anguidine potentiates cisplatinum in human brain tumor cells. J neuro-Onc 3: 343–348, 1986
Bergert JP, Drewinko B, Corry P, Barlogie B, Ho DH: Synergistic lethal effect of cis-dichlorodiamineplatinum and 1-B-D arabinofuranosylcytosine. Cancer Res 41: 25–30, 1981
Stewart DJ, Hugenholtz H, DaSilva V, Benolt B, Richard M, Russdi N, Marsen J, Verma S: Cytosine arabinoside plus cisplatin and other drugs as chemotherapy for gliomas. Seminars in Onc 14: 110–115, 1987 (Suppl)
Kyriazis AP, Kyriazis AA, Martelo AJ: Response to single agent and combination chemotherapy to a human prostatic carcinoma grown in nude mice. Proc Am Assoc, Can Res 22: 211, 1981
Lai GM, Ozohs RE, Smith JF: Enhanced DNA repair and resistance to cisplatin in human ovarian cancer. Biochem Pharmacol 37: 4597–4600, 1988
Eder JP, Teicher BA, Holden SA, Cathcart KRS, Schnipper Le, Frei E: Effect of novobiocin on the antitumor activity and tumor cell and bone marrow survivals of the alkylating agents. Cancer Res 49: 595–598, 1989
Onoda JM, Nelson KK, Taylor JD, Honn KV:In vivo characterization of combination antitumor chemotherapy with calcium channel blockers and cis-diamminedichloroplatinum II. Cancer Res 49: 2844–2850, 1989
Teicher BA, Herman TS, Holden SA, Epelbrum R, Liu S, Frei E: Lonidamine as a modulator of alkylating agent activityin vitro andin vivo. Cancer Res 51: 780–784, 1991
Russo A, DeGraff W, Freedman N, Mitchell JB: Selective modulation of glutathione levels in human normal versus tumor cells and subsequent differential response to chemotherapy drugs. Cancer Res 46: 2845–2848, 1986
Herman TS, Teicher BA, Chan V: Effect of heat on the cytotoxicity and interaction with DNA of a series of platinum complexes. Int J Radiat Oncol Biol Physiol 16: 433–4501, 1989
Scanlon K, Wong H, Han H: Cyclosporin A suppresses cis-platin-induced oncogene expression in human cancer cells. Cancer Treat Res 17: 27, 1990
Basu A, Kozikowski AP, Soto K, Lazo JS: Cellular sensitization to cis-diammindichloroplatinum II by novel analogues of the protein kinase C activates lyngbyatoxin A. Cancer Res 51: 2511–2514, 1991
Boike GM, Averette HG, Chou TC: Enhanced cisplatin cytotoxicity and modulation of cisplatin-induced cell cycle perturbations by caffeine and pentoxifylline in gynecologic cancer cell lines. Proc Am Assoc Cancer Res 32: 408, 1991
Wilkhoff LJ, Dulmodge EA, Trader MW: Evaluation of trans-tetrachloro-1,2-diamminocyclohexane platinum (IV) in murine leukemia L1210 resistant and sensitive to cis-diamminedichloroplatinum (II). Cancer Chemother Pharmacol 20: 96–99, 1987
Cabral FR, Brady RC, Schlber MJ: A mechanism of cellular resistance to drugs that interfere with microtubule assembly. Ann NY Acad Sci 46: 748–756, 1986
Lee WC, Lin KY, Chen KN, Lai YK: Induction of HSP70 is associated with vincristine resistance in heat-shocked 9L rat brain tumor cells. Br J of Cancer 66: (4) 653–659, 1992
Meltzer PS, Dalton WS, Grogan: Drug resistance in multiple myeloma and non-Hodgkin's lymphoma: Detection of p-glycoprotein and potential circumvention by addition of verapamil to chemotherapy. J Clin Oncol 7: 415–424, 1989
Tirelli U, Incalci M, Caretta R, Tumolo S, Franchin G, Veronesa A, Galligione E, Trovo MG, Rossi C, Grigoletto E: Etoposide (VP16-213) in malignant brain tumors: A phase II study. J Clin Oncol 2: 432–437, 1984
Sklansky BD, Mann-Kaplan RS, Reynolds Jr AF, Rosenblum ML, Walker MD: 4′-demethyl-epipodophyllotoxin-B-d-thenylidene-glucoside (PTG) in the treatment of malignant intracranial neoplasms. Cancer 33: 460–467, 1974
Yang L, Row TC, Liu LF: Identification of DNA topoisomerase II as an intracellular target of antitumor epipodophyllotoxins in simian virus 40-infected monkey cells. Cancer Res 45: 5872–5876, 1985
Lee T, Roberts D: Flux of Teniposide (VM-26) across the plasma membrane of teniposide resistant sublines of L1210 cells. Cancer Res 44: 2986–2990, 1984
Hill BT, Bellamy AS: Establishment of an etoposide-resistant human epithelial tumor cell linein vitro: Characterization of patterns of cross-resistance and drug sensitivities. In J Cancer 33: 599–608, 1984
Glisson B: Characterization of acquired epipodophyllotoxin-resistant Chinese hamster ovary cell lines: loss of drug-stimulated DNA cleavage activity. Cancer Res 46: 1934–1938, 1986
Pommier Y, Kerrigan D, Schwartz RE: Altered DNA topoisomerase II activity in Chinese Hamster cells resistant to topoisomerase II inhibitors. Cancer Res 46: 3075–3081, 1986
Hellman R, Fishman H, Calogero J, Kaplan B: Etoposide (VP-16), vincristine (VCR) and procarbazine (P) with radiation therapy for the treatment of glioblastoma multiforme (GBM) final analysis. Proc Am Soc Clin Oncol 13: 181, 1994
Taylor S, Cowley J, Pollock TW, Eyre HJ, Jaeckle C, Hyre HE, Stephens RL: Objective antitumor activity of acivicin in patients with recurrent CNS malignancies: A Southwest Oncology Group Trial. J Clin Oncol 9: 1476–1479
Feun LG, Yung WKA, Leavens MC, Burgess MA, Obbers E, Bedikian AY, Savaraj N, Stewart DJ, Benjamin RS, Fields WS, Bodey GP: A Phase II trial of 1,5-diaziridinyl-3,6 bis (carboethoxyamino) 1,4, benzoquinone (AZQ) NSC 182986) in recurrent primary brain tumors. J Neuro-Onc 2: 13–17, 1984
O'Reilly SM, Newlands ES, Glaser MG, Brampton M, Stevens MFG: Temozolomide: a new oral cytotoxic agent with promising activity against gliomas. Proc Am Soc Clin Oncol 12: 176, 1993
Endicott JA, Ling V: The biochemistry of P-glycoproteinmediated multidrug resistance. Annu Rev Biochem 58: 137–171, 1989
Van der Bliek A, Borst P: Multidrug resistance. Adv Can Res 52: 165–203, 1989
Gerlach JH, Kartner N, Bell D, Ling V: Multidrug resistance. Cancer Survey 5: 25–46, 1986
Lampidis T, Savaraj N, Valet G, Fourcade A, Tapeiro H: Relationship of chemical charge of anticancer agents to drug accumulation and cytotoxicity in cardiac and tumor cells: Relevance to multidrug resistance. In: Anticancer drugs. Colloque Inserm, vol 191, pp 29–38. John Libbey Publisher, London, 1989
Chen C, Chin JE, Ueda K, Clark DP, Pastan I, Gottesman MM, Roninson IB: Internal duplication and homology with bacterial transport proteins in themdrl (P-glycoprotein) gene from multidrug-resistant human cells. Cell 47: 381–389, 1986
Raymon M, Rose E, Housman D, Gros P: Physical mapping, amplification, and overexpression of the mousemdr gene family in multidrug-resistant cells. Mol Cell Biol 10: 1642–1651, 1990
Roninson IB, Pastan J, Gottesman MM: (1991) In: Roninson IB (ed) Molecular and cell biology of multidrug resistance in tumor cell (Plenums New York) pp 91–106
Lincke CR, Smit JM, van der Velde-Koerts T, Borst P: Structure of the humanMDR3 and physical mapping of the humanMDR Locus. J Biol Chem 266: 5303–5310, 1991
Pastan I, Gottesman MM: Multiple-drug resistance in human cancre. New Eng J Med 316: 1388–1393, 1987
Goldstein LJ, Galski H, Fojo A, Willingham M, Lai SL, Gazdar A, Parker R, Green A, Christ Net al.: Expression of a multidrug resistance gene in human cancer. J Natl Cancer Inst 81: 116–124, 1989
Cardon-Cardo C, O'Brien JP, Boccia J, Casalo D, Bertino JR, Melamed MR: Expression of the multidrug resistance gene product (P-glycoproteins) in human normal and tumor tissue. The J of Histo and Cytochem 38: 1277–1287, 1990
Matsumoto T, Tani E, Kaba K, Kochi N, Shindo H, Miyaji K: Amplification and expression of a multidrug resistance gene in human glioma cell line. J neurosurg 72: 96–101, 1990
Tishler DM, Raffel C: Development of multidrug resistance in a primitive neuroectodermal tumor cell line. J Neurosurg 76: 502–506, 1992
Feun L, Landy H, Lu K, Li DJ, Kuo MT, Lampidis T, Green B, Savaraj N: MDRl gene expression in primary brain tumor (MBT) Proc Am Soc Clin One 8: 88, 1989
Nabors NW, Zehnbauer BA, Kaufman SH, Grossman SA, Zhao XL, Breem H, Long DM, Chu YW, Phillips PC, Calvin OM: MDR gene expression in human tumors. Proc Am Assoc of Cancer Res 31: 355, 1990
Matsumoto T, Tani E, Kaba, Shindo H, Miyaji K: Expression of P-glycoprotein in human glioma cell lines and surgical glioma specimens. J Neurosurg 74: 460–466, 1991
Tisher D, Weinberg KI, Sender LS, Nolta J, Raffel C: Multidrug resistance gene expression in pediatric primitive neuroectodermal tumors of central nervous system. J Neurosurg 76: 507–512, 1992
Herzog CE, Trepel JB, Mickley LA, Bates SE, Fojo AT: Various methods of analysis of mdrl/P-glycoprotein in human colon cancer cell lines. J natl Cancer Inst 84: 711–714, 1992
Ford JM, Hait WN: Pharmacology of drugs that alter multidrug resistance in cancer. Pharmacol Rev 42: 155–199, 1990
Trumper LH, Ho AD, Wulf G, Hunstein W: Addition of Verapamil to overcome drug resistance in multiple myeloma: Preliminary clinical observations in 10 patients. J Clin Oncol 7: 1578–1579, 1989
Miller TP, Grogan TM, Dalton WS, Spier CM, Scheper RJ, Jahman Se: P-glycoprotein expression in malignant lymphoma and reversal of clinical drug resistance with chemotherapy plus high-dose Verapamil. J Clin Oncol 9: 17–24, 1991
Marquardt D, McCrones, Center MS: Mechanisms of multidrug resistance in HL-60 cells: Detection of resistance-associated proteins with antibodies against synthetic peptides that correspond to the reduced sequence of P-glyco-protein. Cancer Res 50: 1426–1430, 1990
Cole SPC, Bhardaj G, Gerlach JH, Mackie JE, Grant CE, Almquist KC, Stewart AJ, Kurz Eu, Duncan AMV, Deeley RG: Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science 258: 1650–1654, 1992
Zaman GJR, Versantwoort CHM, Smith JJM, Eijdems EWHM, de Haas M, Smith AJ, Broxterman HJ, Mulder NH, de Vries EGE, Baas F, Borst P: Analysis of the expression of MRP, the gene for a new putative transmembrane drug transporter in human multidrug resistant lung cancer cell line. Cancer Res 53: 1747–1750, 1993
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Feun, L.G., Savaraj, N. & Landy, H.J. Drug resistance in brain tumors. J Neuro-Oncol 20, 165–176 (1994). https://doi.org/10.1007/BF01052726
Issue Date:
DOI: https://doi.org/10.1007/BF01052726